Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Related Research units
Abstract
Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 7 |
| ISSN | 0732-183X |
| Publication status | Published - 2011 |
| pubmed | 21189395 |
|---|
